Literature DB >> 35867525

Reply to Epling and Powers, "Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients".

Marco Falcone1, Giusy Tiseo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35867525      PMCID： PMC9380543          DOI： 10.1128/aac.00795-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


× No keyword cloud information.
  18 in total

1.  Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.

Authors:  Rujipas Sirijatuphat; Visanu Thamlikitkul
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial.

Authors:  Hye Jung Park; Jae Hwa Cho; Hyung Jung Kim; Sang Hoon Han; Seok Hoon Jeong; Min Kwang Byun
Journal:  J Glob Antimicrob Resist       Date:  2018-11-23       Impact factor: 4.035

3.  Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Authors:  François Raffi; Hans Jaeger; Eugenia Quiros-Roldan; Helmut Albrecht; Elena Belonosova; Jose M Gatell; Jean-Guy Baril; Pere Domingo; Clare Brennan; Steve Almond; Sherene Min
Journal:  Lancet Infect Dis       Date:  2013-09-25       Impact factor: 25.071

4.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).

Authors:  Mical Paul; Elena Carrara; Pilar Retamar; Thomas Tängdén; Roni Bitterman; Robert A Bonomo; Jan de Waele; George L Daikos; Murat Akova; Stephan Harbarth; Celine Pulcini; José Garnacho-Montero; Katja Seme; Mario Tumbarello; Paul Christoffer Lindemann; Sumanth Gandra; Yunsong Yu; Matteo Bassetti; Johan W Mouton; Evelina Tacconelli; Jesús Rodríguez-Baño
Journal:  Clin Microbiol Infect       Date:  2021-12-16       Impact factor: 8.067

5.  Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Marco Falcone; Giusy Tiseo; Alessandro Leonildi; Leonardo Della Sala; Alessandra Vecchione; Simona Barnini; Alessio Farcomeni; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2022-03-21       Impact factor: 5.938

6.  Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.

Authors:  Emanuele Durante-Mangoni; Giuseppe Signoriello; Roberto Andini; Annunziata Mattei; Maria De Cristoforo; Patrizia Murino; Matteo Bassetti; Paolo Malacarne; Nicola Petrosillo; Nicola Galdieri; Paola Mocavero; Antonio Corcione; Claudio Viscoli; Raffaele Zarrilli; Ciro Gallo; Riccardo Utili
Journal:  Clin Infect Dis       Date:  2013-04-24       Impact factor: 9.079

7.  Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study.

Authors:  Demosthenes Makris; Efi Petinaki; Vasssiliki Tsolaki; Efstratios Manoulakas; Konstantinos Mantzarlis; Olimpia Apostolopoulou; Dimitrios Sfyras; Epaminondas Zakynthinos
Journal:  Indian J Crit Care Med       Date:  2018-02

8.  RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

Authors:  Johann Motsch; Cláudia Murta de Oliveira; Viktor Stus; Iftihar Köksal; Olexiy Lyulko; Helen W Boucher; Keith S Kaye; Thomas M File; Michelle L Brown; Ireen Khan; Jiejun Du; Hee-Koung Joeng; Robert W Tipping; Angela Aggrey; Katherine Young; Nicholas A Kartsonis; Joan R Butterton; Amanda Paschke
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

9.  Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.

Authors:  H Aydemir; D Akduman; N Piskin; F Comert; E Horuz; A Terzi; F Kokturk; T Ornek; G Celebi
Journal:  Epidemiol Infect       Date:  2012-09-07       Impact factor: 4.434

10.  Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.

Authors:  Matteo Bassetti; Roger Echols; Yuko Matsunaga; Mari Ariyasu; Yohei Doi; Ricard Ferrer; Thomas P Lodise; Thierry Naas; Yoshihito Niki; David L Paterson; Simon Portsmouth; Julian Torre-Cisneros; Kiichiro Toyoizumi; Richard G Wunderink; Tsutae D Nagata
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 71.421
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.